Profound Medical Corp. SEC filings document regulatory disclosures for a commercial-stage medical device company focused on interventional MRI procedures. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD disclosures, furnished press releases, revenue guidance and business updates tied to TULSA-PRO®, the TULSA Procedure™ and Sonalleve®.
The filing record also includes clinical and commercial disclosure categories, such as CAPTAIN trial updates, scientific-meeting presentations and TULSA Procedure adoption milestones. Governance filings record director changes and board appointments, while exchange-act cover disclosures identify the company’s common shares registered on Nasdaq under the PROF symbol.
Profound Medical Corp. furnished an update under Regulation FD noting clinical use of its Sonalleve technology. On February 5, 2026, the Company announced that the PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure, marking a notable usage milestone at that site.
Profound Medical Corp. furnished a current report to let investors know it has issued a press release announcing upcoming investor events. The company attached this press release as Exhibit 99.1 so readers can access the full details of those events.
The company specifically states that the information about these investor events, including the exhibit, is being provided under Regulation FD and is considered "furnished" rather than "filed" under U.S. securities laws. This means it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
Profound Medical Corp. reported that Mount Sinai Hospital has treated its first prostate cancer patient using the company’s TULSA-PRO® system. This update was shared through a press release dated January 15, 2026, which is included as an exhibit to the report. The disclosure is made under Regulation FD, meaning the company is sharing this operational milestone to keep all investors informed at the same time.
Profound Medical Corp. filed a current report to share an operational update on its TULSA-PRO® technology platform. The company announced in a press release that its installed base of TULSA-PRO® systems stood at 78 systems as of December 31, 2025. This figure reflects the number of systems placed at customer sites by the end of the year.
The press release containing this information is furnished as an exhibit and is not deemed filed for liability purposes under U.S. securities laws or incorporated by reference into other SEC filings.
Profound Medical Corp. filed a preliminary Form S-3 shelf registration to offer, from time to time after effectiveness, up to $150,000,000 of securities. The shelf covers common shares, warrants, debt securities, subscription receipts, and units, with specific terms and pricing to be set in future prospectus supplements.
Sales may occur through underwriters, dealers, agents, directly to investors, or via methods such as at-the-market or equity line transactions, as described in the plan of distribution. Net proceeds will be used for working capital, capital expenditures, and general corporate purposes, and may include investments or acquisitions noted in future supplements.
The company’s common shares trade on Nasdaq as “PROF” and on the TSX as “PRN”; on November 12, 2025, closing prices were $6.47 (Nasdaq) and C$9.05 (TSX). Shares outstanding were 30,193,592 as of the date of this prospectus.
Profound Medical Corp. reported Q3 2025 results and highlighted liquidity risks. Revenue rose to $5.289 million, up 87% year over year, driven by U.S. capital sales and higher recurring revenue. Gross margin improved to 74% from 63% as manufacturing efficiency and mix shifted toward higher‑margin systems. Net loss was $7.977 million, narrowing from $9.365 million.
For the nine months ended September 30, 2025, revenue was $10.121 million and net loss totaled $34.395 million, with operating cash outflow of $31.641 million. Cash was $24.826 million and working capital was $31.586 million as of September 30, 2025. Long‑term debt was presented as current at $4.480 million due to a projected covenant breach by June 30, 2026 under the CIBC Credit Agreement. Management disclosed substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing. As of November 13, 2025, 30,193,592 common shares were outstanding.
The company continues remediation of a previously identified material weakness in revenue recognition controls.
Profound Medical Corp. (PROF) announced it has entered into an exclusive distribution and supply agreement with Getz Healthcare for its TULSA-PRO system in Australia and New Zealand. The company disclosed the news under Regulation FD, indicating a commercial channel partner will handle market distribution in these regions.
The announcement was provided via a press release furnished as Exhibit 99.1. As furnished information under Item 7.01, it is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Profound Medical Corp. (PROF) announced it entered into an exclusive distribution and supply agreement in Saudi Arabia with Al Faisaliah Medical Systems Co. covering its TULSA-PRO and Sonalleve technologies. The company disclosed the news via a press release furnished under Item 7.01 (Regulation FD).
The agreement designates a single distributor for these systems in Saudi Arabia, signaling a focused commercial pathway for Profound Medical’s prostate ablation (TULSA-PRO) and MR-guided therapeutic ultrasound (Sonalleve) platforms in that market. The press release was furnished as Exhibit 99.1.
Profound Medical Corp. reported under Regulation FD that it has regained exclusive distribution rights for its TULSA-PRO product in Canada from Knight Therapeutics Inc. The company announced the change in a press release dated November 10, 2025, which is furnished as Exhibit 99.1.
The Item 7.01 disclosure notes the press release is furnished, not filed, and is not incorporated by reference into other SEC filings.
Profound Medical Corp. filed a current report to note that it issued a press release on October 7, 2025 announcing certain preliminary unaudited financial results for the three months ended September 30, 2025 and providing a business update. The press release is furnished as Exhibit 99.1 under Item 2.02, which covers results of operations and financial condition. The company states that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.